## ISRG: Intuitive Surgical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.4% below STRENGTH zone (4.0-10.0%); PEG 3.36 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($528.56)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Intuitive Surgical Stock (ISRG) News Today: Price Action, Analyst Forecasts, and What to Watch on December 16, 2025**
- Source: ts2.tech | 20251216T170827 | Somewhat-Bullish | Relevance: 100%
- Intuitive Surgical (ISRG) saw a 2% intraday dip on December 16, 2025, to $548-$549, following a strong rebound, with its market cap around $194 billion. The stock is drawing attention due to improving "Relative Strength" signals, institutional rebalancing, insider selling, and analyst forecasts for its continued growth into 2026. Key catalysts include the recent FDA clearance expanding da Vinci SP indications, and investors are keenly watching Q4 results in late January 2026 for further signals on procedure growth and system placements.

**2. Stocks showing improving market leadership: Intuitive Surgical earns 81 RS rating**
- Source: MSN | 20251216T160116 | Bullish | Relevance: 100%
- Intuitive Surgical (ISRG) has seen an improvement in its Relative Strength (RS) Rating, which increased from 79 to 81. This upgrade indicates a stronger performance compared to other stocks in the market. The RS Rating is a crucial indicator for investors looking for top-performing stocks.

**3. Intuitive Surgical (ISRG) Stock After Hours: What Happened on Dec. 15, 2025—and What to Watch Before Tuesday’s Open**
- Source: ts2.tech | 20251216T013857 | Somewhat-Bullish | Relevance: 100%
- Intuitive Surgical (ISRG) saw a rebound on Monday, December 15, 2025, closing up 3.17% at $559.52, but then experienced a modest dip in after-hours trading. A key development was an insider Form 4 filing related to a planned sale of shares by an executive, which is unlikely to impact long-term fundamentals but could influence short-term sentiment. Heading into Tuesday, investors should also monitor significant U.S. economic data releases, particularly the rescheduled retail sales figures.

**4. Intuitive Surgical (ISRG) stock: What to know before the U.S. market opens on Dec. 15, 2025**
- Source: ts2.tech | 20251214T221221 | Neutral | Relevance: 100%
- This article provides a comprehensive overview of key factors influencing Intuitive Surgical (ISRG) stock before the market opens on December 15, 2025. It highlights recent FDA clearances for its da Vinci SP system, increasing competition from Medtronic and Johnson & Johnson, Q3 2025 financial performance, ongoing product momentum, and analyst forecasts, all while considering the stock's premium valuation.

**5. Nilsine Partners LLC Sells 7,507 Shares of Intuitive Surgical, Inc. $ISRG**
- Source: MarketBeat | 20251216T130533 | Neutral | Relevance: 100%
- Nilsine Partners LLC significantly reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 51.8% in Q3, selling 7,507 shares and holding 6,986 shares valued at $3.12 million. Insider selling also occurred, with executives selling 114,007 shares collectively worth $63.53 million, leaving insiders with 0.70% ownership. Despite this, Intuitive Surgical reported strong quarterly earnings, beating analyst expectations, and maintains a "Moderate Buy" consensus with an average target price of $608.79.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $635 | $650 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($2.31M) |
| Sells | 14 ($32.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 35.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.8%)
- Blackrock Inc.: 8.8% (+0.1%)
- State Street Corpora: 4.3% (-0.1%)
- Price (T.Rowe) Assoc: 3.6% (-4.4%)
- Geode Capital Manage: 2.3% (+1.0%)

### Key Risks

1. Heavy insider selling: $32M sold (14 transactions in 90 days).
2. Valuation stretched: PEG 3.4x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.36 signals overvaluation risk, limited margin of safety. Forward P/E 56.9x stretched relative to 13% growth. Quality metrics strong (margin 29%). Balance sheet: strong liquidity (4.7x), low leverage (D/E 0.14). Analyst sentiment negative (1 target cuts vs 0 raises). Insider selling cluster ($32.3M in 90 days), potential headwind. Institutional flow bearish (4 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $198.8B |
| Beta | 1.69 |
| 52W Range | $425.00 - $616.00 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.36 |
| Forward P/E | 56.9 |
| Current P/E | 64.2 |
| YoY Growth | 12.7% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -3.9% to -1.4% (+2.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.3pp (needs >4.0% for momentum thesis). MRS_5 turning positive (1.4%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). MACD histogram bearish (-4.41), momentum weakening. RSI neutral at 51. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.35% (CS: 30) | Neutral |
| RSI_14 | 50.7 | Neutral |
| MACD Histogram | -4.41 | Bearish |
| vs SMA20 | 0.986x | Below |
| vs SMA50 | 1.044x | Above |
| vs SMA200 | 1.092x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $554.58
- **Stop Loss:** $528.56 (4.7% risk)
- **Target:** $580.60 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 38
- **Position Value:** $21,074.04
- **Portfolio %:** 21.07%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-01-22 (Est: $2.24)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.99 | $2.40 | +20.7% |
| 2025Q2 | $1.92 | $2.19 | +14.1% |
| 2025Q1 | $1.73 | $1.81 | +4.4% |
| 2024Q4 | $1.79 | $2.21 | +23.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*